Back

29 August 2024

Olympic Games Paris 2024 – the ITA sanctions Bolivian athlete María José Ribera Pinto

The International Testing Agency (ITA) reports that a sample collected from swimmer María José Ribera Pinto (Bolivia) has returned an Adverse Analytical Finding¹ for the specified prohibited substance furosemide (classified as S5. Diuretics and Masking Agents according to the Prohibited List of the World Anti-Doping Agency (WADA)).

The sample was collected by the ITA under the testing authority and results management authority of the International Olympic Committee (IOC) during an In-Competition anti-doping control on 3 August 2024 in Paris, France. The result was reported by the WADA-accredited laboratory of Paris on 5 August 2024.

Pursuant to the athlete’s request, on 8 August 2024 her B-sample was opened and analysed. The athlete attended the process, along with her representative. The B-sample analysis confirmed the presence of furosemide.

The athlete accepted the consequences of her Anti-Doping Rule Violation (ADRV) under the IOC Anti-Doping Rules applicable to the Olympic Games Paris 2024, i.e. (i) the finding of the ADRV, (ii) Ineligibility for the Olympic Games Paris 2024 and (iii) Disqualification of 28th place results in the Women’s Swimming Sprint 100m at the Olympic Games Paris 2024.

The matter is considered as concluded from the perspective of the IOC and has been referred to World Aquatics for a determination of further consequences.

There will be no further comments on this case.

¹A report from a WADA-accredited laboratory that, consistent with the International Standard for Laboratories, establishes in a Sample the presence of a Prohibited Substance or its Metabolites or Markers or evidence of the Use of a Prohibited Method.

Share

Cookie Policy & Privacy Notice

We use cookies on our website to personalize content, to analyze traffic on our website to provide social media features. We share your data with our analytics partners and social media content providers. Find out more

The privacy policy can be accessed here

Your current state: Consent rejected.


Accept Reject Read More